InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Engages Veloxity Labs for IND-Enabling Study of PTSD Drug SPC-15
Silo Pharma (NASDAQ: SILO) has partnered with Veloxity Labs to conduct GLP-compliant bioanalysis for its ongoing toxicology and toxicokinetics study of SPC-15, an intranasal treatment aimed at preventing PTSD. The data will support an FDA investigational new drug submission expected in 2025. If approved, Silo plans to advance SPC-15 into a Phase 1 human clinical trial. To view the full press release, visit https://ibn.fm/Bo8ag About…